The firm is a European venture capital firm focused on early-stage technology and healthcare investments. The firm primarily invests at the Seed and Series A stages, with selective participation in Series B financings and significant follow-on capacity. Initial investments typically range from approximately €500K to €3M, with total commitments of up to €10M–15M per portfolio company. The firm has established a dedicated healthcare investment platform supported by strategic partners across the healthcare ecosystem and primarily invests in companies across Europe.  

The firm focuses primarily on digital health, including health data platforms, diagnostics, care delivery technologies, clinical workflow solutions, and other enabling healthcare technologies. The firm also selectively invests in medical technology companies, particularly those incorporating connected care, artificial intelligence, or digital components. The firm seeks businesses with differentiated technologies capable of improving clinical outcomes or healthcare system efficiency.  

From a company and management team perspective, the firm is an active investor that frequently serves as lead investor and consistently takes a board seat. The firm works closely with portfolio companies on corporate strategy, financing, talent recruitment, business development, and strategic partnerships, providing hands-on operational support throughout the company’s growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture capital arm of a global pharmaceutical company invests in innovative digital health companies worldwide. Established in 2015, the firm supports companies from Seed through later-stage venture financings and can invest up to approximately $5M per financing round. The firm seeks strategic investments that complement its parent company’s long-term healthcare priorities while helping portfolio companies accelerate product development and commercial adoption. 

The firm focuses exclusively on digital health, with particular interest in prevention and medication adherence technologies, digital therapeutics, digital medical devices, and big data analytics platforms. Key areas of interest include chronic diseases such as diabetes, obesity, and cardiovascular disease, as well as respiratory diseases, oncology, consumer health, and mental health. The firm seeks innovative technologies that improve patient outcomes through connected care, data-driven insights, and digital healthcare solutions. 

From a company and management team perspective, the firm prefers experienced leadership teams with demonstrated expertise in their respective markets and well-developed business plans. The firm partners with companies globally and seeks management teams capable of successfully commercializing innovative digital health technologies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The U.S.-based research and business development arm of a global pharmaceutical company serves as its international innovation and partnering platform. Rather than operating as a traditional venture capital investor, the firm identifies and evaluates external innovation to strengthen the parent company’s research and development pipeline. The firm collaborates with biotechnology and pharmaceutical companies worldwide through strategic partnerships, in-licensing, co-development, and other business development transactions to accelerate the advancement of innovative medicines. The firm focuses on therapeutic innovation across anti-infectives, central nervous system disorders, oncology, autoimmune diseases, and metabolic diseases.  

The firm is open to a broad range of therapeutic modalities and actively seeks novel drug candidates, platform technologies, and translational research programs that align with its strategic development priorities. The firm evaluates opportunities across preclinical and clinical development and pursues flexible partnership structures tailored to the needs of each program.  

From a company and management team perspective, the firm seeks partners with differentiated science, strong intellectual property, and compelling preclinical or clinical data supporting global development potential. The firm values companies with well-defined development strategies and innovative assets that can address significant unmet medical needs. Through its global development, regulatory, manufacturing, and commercialization capabilities, the firm works closely with partners to advance promising therapies toward international markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a healthcare-focused venture capital firm based in the United States that invests in novel, differentiated therapeutics addressing significant unmet medical needs. The firm makes direct equity investments across the full development spectrum, from preclinical programs through clinical- and commercial-stage companies. The firm participates in Seed and first institutional rounds, later-stage private financings, crossover rounds, and PIPE transactions, with the capacity to invest up to approximately $15M over the life of an investment. The firm can act as a lead, co-lead, or co-investor and invests in both private and public companies.  

The firm focuses primarily on therapeutics in oncology, immunology, neurology, and rare diseases, while remaining open to other indications on a selective basis. The firm is stage-agnostic and prioritizes differentiated science, strong biological rationale, and programs with meaningful clinical and commercial potential. The firm seeks opportunities capable of addressing substantial unmet needs and reaching important development, regulatory, or commercial value-inflection milestones.  

From a company and management team perspective, the firm prefers experienced leadership teams with strong scientific and drug development expertise. The firm partners closely with scientists, entrepreneurs, and institutional co-investors and provides strategic support through its pharmaceutical and healthcare industry network. The firm seeks to help portfolio companies advance toward clinical milestones, strategic partnerships, follow-on financings, and successful exits.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a venture capital firm focused on supporting innovative healthcare companies across Asia, Australia, and North America. The firm invests in emerging life sciences businesses developing differentiated technologies and seeks opportunities with strong clinical and commercial potential. The firm takes a cross-border investment approach, helping portfolio companies access international capital, strategic partnerships, and global growth opportunities.  

The firm invests across biopharmaceuticals, medical devices, and digital health, with a particular interest in novel therapeutics addressing significant unmet medical needs. Areas of interest include immuno-oncology, neuroscience, and other high-impact therapeutic innovations. The firm is open to companies at all stages of clinical development and evaluates opportunities based on the strength of the underlying science, clinical potential, and market opportunity.  

From a company and management team perspective, the firm seeks innovative companies developing differentiated technologies with the potential to address meaningful unmet healthcare needs. The firm partners with management teams to support clinical development, commercialization, and international expansion, leveraging its cross-border network and experience in global healthcare investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a venture capital firm founded by experienced biotechnology entrepreneurs and focused exclusively on novel therapeutics. The firm invests at the earliest stages of company development, from Seed through late preclinical programs, and typically supports portfolio companies through clinical proof-of-concept before pursuing strategic exit opportunities. The firm generally makes initial equity investments of approximately $3M–5M, with the capacity to invest up to $15M–20M per company over the life of an investment. Investments are primarily made through equity, although convertible structures may be used selectively. While the firm’s current portfolio has a strong European focus, it takes a globally opportunistic approach and is expanding its focus toward North American opportunities.  

The firm invests exclusively in therapeutics and is both modality- and indication-agnostic. The firm prioritizes highly innovative drug candidates with differentiated mechanisms of action, compelling scientific rationale, and significant unmet medical need. Rather than focusing on specific therapeutic areas, the firm emphasizes development stage, scientific quality, and commercial potential. In addition to participating in financing syndicates, the firm is also active in company creation and the formation of new biotechnology ventures.  

From a company and management team perspective, the firm values experienced founders and leadership teams but does not impose strict requirements. The investment team works closely with portfolio companies on R&D strategy, capital allocation, financing, and corporate development, leveraging longstanding relationships with academic researchers, entrepreneurs, and biotechnology investors to help companies reach critical value-inflection milestones. The firm is open to acting as either a lead investor or co-investor depending on the opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.